Zusammenfassung
Mikroskopische Frakturen (sog. „microcracks“) und unfallbedingte makroskopische Frakturen erfordern von Knochen als Grundgerüst des menschlichen Körpers eine hohe Regenerationsfähigkeit. Um diesen Anforderungen genügen zu können, sind sie permanenten Umbau- und Erneuerungsprozessen unterworfen. Ist die Knochenhomöostase jedoch gestört, führt dies zu Osteoporose oder anderen Knochenerkrankungen. Da das Immunsystem wesentlich an der Regulation der Knochenhomöostase beteiligt ist und insbesondere chronische Entzündungen diese aus dem Gleichgewicht bringen können, werden im Rahmen dieses Beitrags die osteoimmunologischen Aspekte beleuchtet, die zur Entstehung von Osteoporose und anderen Erkrankungen, die mit einer Knochendegradation einhergehen, beitragen.
Abstract
Microscopic fractures (so-called microcracks) or traumatic macrofractures require bone, as the basic scaffold of the human body, to have a high regenerative capability. In order to be able to provide this regenerative capability, bone is in a constant process of remodeling. This finely tuned homeostasis of bone formation and degradation can become disrupted, which leads to osteoporosis or other bone disorders. It has been shown that the immune system is substantially involved in the regulation of bone homeostasis and that chronic inflammation in particular can disturb this balance; therefore, this article reviews the osteoimmunological aspects contributing to osteoporosis and other diseases associated with bone degradation.
Literatur
Axmann R, Herman S, Zaiss M et al (2008) CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis 67:1603–1609
Chen G, Deng C, Li YP (2012) TGF-beta and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci 8:272–288
Cohen SB, Dore RK, Lane NE et al (2008) Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58:1299–1309
Deodhar AA, Woolf AD (1996) Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Rheumatology 35:309–322
Frommer KW, Neumann E, Lange U et al (2014) Adipokine und Knochenstoffwechsel – gibt es einen Link? Aktuelle Rheumatol 36:375–383
Gough A, Sambrook P, Devlin J et al (1998) Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 25:1282–1289
Harre U, Georgess D, Bang H et al (2012) Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 122:1791–1802
Jarrett SJ, Conaghan PG, Sloan VS et al (2006) Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 54:1410–1414
Jimenez-Boj E, Nöbauer-Huhmann I, Hanslik-Schnabel B et al (2007) Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. Arthritis Rheum 56:1118–1124
Karmakar S, Kay J, Gravallese EM (2010) Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention. Rheum Dis Clin North Am 36:385–404
Kotake S, Udagawa N, Takahashi N et al (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103:1345–1352
Kremer JM, Genant HK, Moreland LW et al (2008) Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 58:953–963
Krishnamurthy A, Joshua V, Haj HA et al (2016) Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann Rheum Dis 75:721-729
Kubota T, Michigami T, Ozono K (2009) Wnt signaling in bone metabolism. J Bone Miner Metab 27:265–271
Lewiecki EM (2014) Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. Ther Adv Musculoskelet Dis 6:48–57
Li J, Sarosi I, Cattley RC et al (2006) Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39:754–766
Mangashetti LS, Khapli SM, Wani MR (2005) IL-4 inhibits bone-resorbing activity of mature osteoclasts by affecting NF-kappa B and Ca2+ signaling. J Immunol 175:917–925
Mirosavljevic D, Quinn JM, Elliott J et al (2003) T‑cells mediate an inhibitory effect of interleukin-4 on osteoclastogenesis. J Bone Miner Res 18:984–993
Morvan F, Boulukos K, Clement-Lacroix P et al (2006) Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 21:934–945
Neumann E, Frommer KW, Vasile M et al (2011) Adipocytokines as driving forces in rheumatoid arthritis and related inflammatory diseases? Arthritis Rheum 63:1159–1169
Neumann E, Schett G (2007) Bone metabolism: molecular mechanisms. Z Rheumatol 66:286–289
Sambrook PN, Ansell BM, Foster S et al (1985) Bone turnover in early rheumatoid arthritis. 1. biochemical and kinetic indexes. Ann Rheum Dis 44:575–579
Sato K, Suematsu A, Okamoto K et al (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203:2673–2682
Schett G, Kiechl S, Weger S et al (2006) High-sensitivity C‑reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med 166:2495–2501
Smolen JS, Avila JC, Aletaha D (2012) Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis 71:687–693
Smolen JS, Han C, Bala M et al (2005) Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 52:1020–1030
Smolen JS, Han C, Heijde DM van der et al (2009) Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 68:823–827
Will R (1989) Osteoporosis in early ankylosing spondylitis: a primary pathological event? Lancet 334:1483–1485
Zaiss MM, Axmann R, Zwerina J et al (2007) Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum 56:4104–4112
Zhang Q, Chen B, Yan F et al (2014) Interleukin-10 inhibits bone resorption: a potential therapeutic strategy in periodontitis and other bone loss diseases. Biomed Res Int 2014:284836
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
K.W. Frommer, E. Neumann und U. Lange geben an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Additional information
Redaktion
U. Lange, Bad Nauheim
G. Schett, Erlangen
Rights and permissions
About this article
Cite this article
Frommer, K.W., Neumann, E. & Lange, U. Entzündung und Knochen. Z Rheumatol 75, 444–450 (2016). https://doi.org/10.1007/s00393-016-0101-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-016-0101-7